Translation of a portable diffuse optical breast scanner probe for clinical application: a preliminary study

Most breast cancer lesions absorb higher levels of near-infrared (NIR) radiation compared to healthy breast tissue due to its increased vascularity. Oxy-hemoglobin (HbO₂) and deoxy-hemoglobin (Hb) primarily found in cancerous vascular lesions, absorbs higher levels of radiation in the 650 nm to 850 nm wavelength range than the surrounding fatty tissue and water in the human breast. NIR diffuse optical spectroscopy (DOS) provides real-time functional and compositional information based on the optical properties of biological tissues, which cannot be accomplished by other portable breast imaging modalities. Here we present the first set of clinical trials using a non-invasive, hand-held diffuse optical breast scanner (DOB-Scan probe³) to capture in vivo cross-sectional images of the breast. The scanner uses four NIR illuminating sources with different wavelengths, 690 nm, 750 nm, 800 nm, and 850 nm, to determine the concentrations of the four main constituents of breast tissue, oxy-hemoglobin (HbO₂), deoxy-hemoglobin (Hb), water (H₂O), and fat. In this paper, we briefly explain the hardware design and image reconstruction algorithm of the DOB-Scan probe, the data collection process, and the imaging results of four different participants, selected from twenty, all who are diagnosed with breast cancer. For each patient, images were scanned from two locations, the first over the cancerous lesion and the second over the same region on the contralateral healthy breast, as a means of establishing controls for comparison. During each scan, four cross-sectional images of the breast, corresponding to four different NIR wavelengths, are reconstructed and displayed on a user interface for reference. Clinical results confirm that the absorption coefficients of cancerous lesions are significantly higher than the normal surrounding tissue. We propose to deploy the probe to effectively identify cancerous breast tissue at an early stage in a primary care setting, which could increase the efficiency of screening programs.